Month: August 2025

Falcon Oil & Gas Ltd (“Falcon”) Native Title holder approval obtained to sell gas under Beneficial Use of Gas legislation 14 August 2025 – Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to announce that an historic agreement has been reached between Falcon Oil & Gas Australia Limited’s (“Falcon Australia”) joint venture partners’ Tamboran (B2) Pty Limited (collectively the “Beetaloo JV partners”) parent company, Tamboran Resources Corporation, with Native Title Holders and the Northern Land Council for the sale of appraisal gas from their Exploration Permits (EP) in the Beetaloo sub-basin (“Agreement”). Points to note:The Agreement provides Native Title Holders’ consent to the Beetaloo JV partners to the sale of appraisal gas from EP98 and EP117 of up to 60 TJ per day from the proposed Shenandoah South Pilot Project...

Bigbank’s loan portfolio grew by 59 million euros in July, marking the largest monthly increase in 2025. The growth was once again driven by focus products: the business loan portfolio expanded by 30 million euros, the home loan portfolio by 20 million euros, and the consumer loan portfolio by 9 million euros. By the end of July, the total loan portfolio reached 2.5 billion euros. The deposit portfolio grew by 71 million euros in July. This growth was led by the savings deposit product, which increased by 73 million euros, while the term deposit portfolio declined by 3 million euros. The trend continues where maturing term deposits are being redirected into the more flexible savings deposit product. The balance of Estonian retail customers’ bank accounts grew by 1.0 million euros during the month, reaching 4.3 million euros by the end...

The Fund has previously, i.e. on 2 April 2025, announced to the stock exchange the acquisition of the property located at Hiiu St 42, Tallinn by its subsidiary EfTEN Hiiu OÜ, and the intention to partially reconstruct the building into a elderly care home, “Nõmme Südamekodu,” which could in the future accommodate up to 170 Südamekodu residents.                  Following the acquisition of the property, EfTEN Hiiu OÜ continued with Nõmme Südamekodu OÜ, a member of the Südamekodu group, and the design company OÜ SIRKEL&MALL on the design of the elderly care home, and carried out a construction procurement.                                                                                                                                                                        The best offer was made by RIS Ehitus OÜ, with whom the construction...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for the potential treatment of complicated urinary tract infections (cUTI), including pyelonephritis. Ceftibuten-ledaborbactam etzadroxil is the combination of ceftibuten, an orally bioavailable cephalosporin antibiotic, and ledaborbactam etzadroxil, the orally bioavailable prodrug of the novel beta-lactamase inhibitor...

Marimekko Corporation, Stock Exchange Release, 14 August 2025 at 8.15 a.m. EEST Marimekko’s financial reporting and Annual General Meeting in 2026 In 2026, Marimekko Corporation will publish financial information as follows:Financial Statements Bulletin 2025 on Thursday 12 February 2026 at 8.00 a.m. Interim Report 1 January–31 March 2026 on Wednesday 13 May 2026 at 8.00 a.m. Half-year Financial Report 1 January–30 June 2026 on Thursday 13 August 2026 at 8.00 a.m. Interim Report 1 January–30 September 2026 on Wednesday 4 November 2026 at 8.00 a.m.Marimekko observes a silent period of 30 days prior to publishing of financial information. The company’s Financial Statements and the Report of the Board of Directors 2025 will be published on the company’s website in week 13, at the latest. Marimekko’s Annual General Meeting is planned to...

Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related diseaseData from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025 Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseasesParis, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). EMA grants orphan designation to investigational therapies addressing rare, life-threatening or debilitating medical diseases or conditions that affect no more than 5 in 10,000 persons in the EU. Rilzabrutinib for the treatment of IgG4-related disease was evaluated in a phase 2 study (clinical study identifier:...